Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 12/2013

01-12-2013 | Short Communication

Clinically silent Crohn’s disease in a patient with Takayasu’s Arteritis unresponsive to conventional therapies

Authors: Neslihan Yilmaz, Meryem Can, Fatma Alibaz-Oner, Haner Direskeneli

Published in: Rheumatology International | Issue 12/2013

Login to get access

Abstract

Takayasu arteritis (TA) and Crohn’s disease (CD) are chronic inflammatory diseases with granulomatous nature. Here, we report a case of TA with a silent course of CD who was refractory to corticosteroid and immunosuppressive treatments and improved with adalimumab therapy.
Literature
1.
Takayasu’s arteritis (2009) EULAR on line course on rheumatic disease
2.
Bernstein CN, Blanchard JF (1999) The epidemiology of Crohn’s disease. Gastroenterology 116:1503–1504PubMedCrossRef
3.
Reny JL, Paul JF, Lefebvre C et al (2003) Association of Takayasu’s arteritis and Crohn’s disease; results of a study on 44 Takayasu patients and review of the literature. Ann Med Intern 154:85–90
4.
Levitsky J, Harrison JR, Cohen RD (2002) Crohn’s disease and Takayasu’s arteritis. J Clin Gastroenterol 34:454–456PubMedCrossRef
5.
Lenhoff SJ, Mee AS (1982) Crohn’s disease of the colon with Takayasu’s arteritis. Postgrad Med J 58:386–389PubMedCrossRef
6.
Farrant M, Mason JC, Wong NA, Longman RJ (2008) Takayasu’s arteritis following Crohn’s disease in a young woman: any evidence for a common pathogenesis? World J Gastroenterol 14:4087–4090PubMedCrossRef
7.
De Simone M, Cioffi U, Quatrini M et al (2006) Crohn’s disease and Takayasu’s arteritis: is this association difficult to find out? Minerva Gastroenterol Dietol 52:441–443PubMed
8.
Comarmond C, Plaisier E, Dahan K et al. (2011) Anti TNF-α in refractory Takayasu’s arteritis: cases series and review of the literature. Autoimmun Rev (Epub Dec 4)
9.
Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS (2008) Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67:1567–1569PubMedCrossRef
10.
Tatò F, Rieger J, Hoffmann U (2005) Refractory Takayasu’s arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab. Int Angiol 24:304–307PubMed
11.
Wasan SK, Kane SV (2011) Adalimumab for the treatment of inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 5:679–684PubMedCrossRef
12.
Cottone M, Criscuoli V (2011) Infliximab to treat Crohn’s disease: an update. Clin Exp Gastroenterol 4:227–238PubMed
13.
Sandborn WJ, Hanauer SB, Katz S et al (2001) Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121:1088–1094PubMedCrossRef
14.
Osman M, Aaron S, Noga M, Yacyshyn E (2011) Takayasu’s arteritis progression on anti-TNF biologics: a case series. Clin Rheumatol 30:703–706 (Epub Jan 2011)PubMedCrossRef
15.
Katoh N, Kubota M, Shimojima Y et al (2010) Takayasu’s arteritis in a patient with Crohn’s disease: an unexpected association during infliximab therapy. Intern Med 49:179–182PubMedCrossRef
Metadata
Title
Clinically silent Crohn’s disease in a patient with Takayasu’s Arteritis unresponsive to conventional therapies
Authors
Neslihan Yilmaz
Meryem Can
Fatma Alibaz-Oner
Haner Direskeneli
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 12/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2558-2

Other articles of this Issue 12/2013

Rheumatology International 12/2013 Go to the issue

Short Communication

Inclusion body myositis associated with Sjögren’s syndrome

Short Communication

Acute cerebral vasculopathy in systemic sclerosis

Letter to the Editor

Nontyphoid Salmonella-infected mycotic aneurysm in a patient with rheumatoid arthritis

Short Communication

Association of interleukin-18 and systemic lupus erythematosus

Original Article

Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database

Short Communication

Mevalonate kinase genotype in children with recurrent fevers and high serum IgD level
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits